- Conditions
- Hepatitis C
- Interventions
- TMC435, Ribavirin (R), PegIFNα-2a (P), Placebo
- Drug
- Lead sponsor
- Tibotec Pharmaceuticals, Ireland
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 386 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Jacksonville, Florida • Orlando, Florida + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 793–816
of 1,163
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Weight
- Interventions
- LIPO-102, LIPO-102 Low, LIPO-102, Placebo
- Drug
- Lead sponsor
- Neothetics, Inc
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 2
- States / cities
- San Diego, California • New York, New York
- Conditions
- Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
- Interventions
- Tirzepatide, Placebo
- Drug · Other
- Lead sponsor
- T. John Winhusen, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 9
- States / cities
- Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 6 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Anti-Thymocyte Globulin (ATG), Granulocyte colony stimulating factor (GCSF), Placebo (for ATG), Placebo (for GCSF)
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 12 Years to 45 Years
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 13
- States / cities
- San Francisco, California • Stanford, California • Aurora, Colorado + 10 more
- Conditions
- Idiopathic Angioedema
- Interventions
- Omalizumab, Placebos
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Acute Stroke, Ischemic Stroke, Stroke
- Interventions
- Recombinant human tissue kallikrein, Placebo for DM199 Solution for Injection
- Drug · Other
- Lead sponsor
- DiaMedica Therapeutics Inc
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 728 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 36
- States / cities
- Fairhope, Alabama • Arcadia, California • Glendale, California + 29 more
- Conditions
- Superficial Thrombophlebitis, Upper Extremity Superficial Thrombophlebitis, Lower Extremity Superficial Thrombophlebitis
- Interventions
- Dalteparin sodium injection
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2011
- U.S. locations
- 2
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- Recombinant human C1 esterase inhibitor, Placebo, SHP623
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Obesity
- Interventions
- ABBV-295, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Anaheim, California • Grayslake, Illinois
- Conditions
- Polycythemia Vera
- Interventions
- Rusfertide, Placebo
- Drug
- Lead sponsor
- Protagonist Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 293 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 80
- States / cities
- Mobile, Alabama • Glendale, Arizona • Duarte, California + 66 more
- Conditions
- Menopause, Aging
- Interventions
- KUVAN, Placebo, Cetrotide, Climara, Placebo transdermal patch
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Osteoarthritis
- Interventions
- Placebo, gevokizumab
- Drug
- Lead sponsor
- XOMA (US) LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 27
- States / cities
- Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 24 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Lixisenatide (AVE0010), Placebo, Insulin glargine, Pen auto-injector, Metformin, Thiazolidinedione (TZD)
- Drug · Device
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 446 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 23
- States / cities
- Mesa, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 19 more
- Conditions
- Myositis, Interstitial Lung Disease
- Interventions
- Abatacept, Placebo
- Drug · Other
- Lead sponsor
- Rohit Aggarwal, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 5
- States / cities
- Beverly Hills, California • Denver, Colorado • Baltimore, Maryland + 2 more
- Conditions
- Hypercholesterolemia
- Interventions
- Alirocumab, Placebo (for alirocumab), Atorvastatin, Placebo (for atorvastatin)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 20
- States / cities
- Mesa, Arizona • Tucson, Arizona • Los Angeles, California + 14 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Lyophilized albiglutide DCC pen injector, Lyophilized albiglutide DCC pen injector matching placebo, Albiglutide liquid auto-injector, Albiglutide liquid auto-injector matching placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 308 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 70
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 62 more
- Conditions
- Sarcoidosis, Pulmonary
- Interventions
- Acthar Gel, Placebo
- Drug
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 26 more
- Conditions
- Moderately to Severely Active Ulcerative Colitis
- Interventions
- Afimkibart, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 46
- States / cities
- Dothan, Alabama • Lancaster, California • Orange, California + 39 more
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Acthar Gel, Placebo
- Drug
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 259 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 30
- States / cities
- San Leandro, California • Upland, California • Boynton Beach, Florida + 23 more
- Conditions
- Gout
- Interventions
- Rilonacept, Placebo (for Rilonacept)
- Biological · Other
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 34
- States / cities
- San Diego, California • Santa Maria, California • Whittier, California + 30 more
- Conditions
- Alzheimer Disease
- Interventions
- bapineuzumab, placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Encino, California + 14 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- tocilizumab SC, tocilizumab IV, placebo to tocilizumab SC, placebo to tocilizumab IV, Disease-modifying antirheumatic drugs (DMARDs)
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,262 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 54
- States / cities
- Huntsville, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 48 more
- Conditions
- Congestive Heart Failure
- Interventions
- Nesiritide, Placebo, Saline
- Drug
- Lead sponsor
- Horng Chen
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Spondylitis, Ankylosing
- Interventions
- Ixekizumab, Placebo, Adalimumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Upland, California + 31 more